Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STAR-0310 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| STAR-0310 Dose 1 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 2 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 3 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 4 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 in Participants of Japanese Descent | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| Name | Type | Description |
|---|---|---|
| STAR-0310 | DRUG | STAR-0310 will be administered as a subcutaneous bolus injection. |
| Placebo | DRUG | Placebo will be administered as a subcutaneous bolus injection. |
Inclusion Criteria: * Good health as determined by the Investigator based upon a medical evaluation. * Body mass index (BMI) of 18 to 35 kg/m2 with a weight of at least 60 kg for men and at least 50 kg for women, with a maximum weight of 130 kg for any participant. * Participants of childbearing po...
STAR-0310 is an investigational small molecule being studied in healthy adult participants. It is currently in Phase 1 clinical development, with an active trial evaluating its safety and tolerability in this population. The drug is not yet approved and remains under investigation.
STAR-0310 targets OX40, a protein involved in immune responses. By targeting OX40, the drug may modulate immune activity, though its precise therapeutic application is still being explored in early-stage clinical trials.
STAR-0310 is being developed by Astria Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ATXS. The company is conducting a Phase 1 study of the drug in healthy volunteers.
STAR-0310 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the drug's safety and pharmacokinetics in healthy participants.
STAR-0310 is being evaluated in a Phase 1 clinical trial with the identifier NCT06782477, titled 'A Study of STAR-0310 in Healthy Adult Participants.' This randomized, double-blind, controlled study is enrolling 40 healthy adults aged 18 years and older in the United States.